A PYMNTS Company

US: FTC asks more questions on Roche’s $5B Spark buy, again

By  |  June 10, 2019

In yet a further delay to the transaction, Swiss pharma giant Roche and Spark Therapeutics announced that they have each received a request for additional information and documentary material from the US Federal Trade Commission (FTC) in connection with the agency’s review of Roche’s pending US$4.3 billion acquisition of Spark announced in February this year.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Issuance of the Second Request is part of the regulatory review process. The effect of the Second Request is to extend the waiting period until 10 days after Roche has substantially complied with the Second Request, unless the waiting period is terminated earlier by the FTC or the parties have entered into a timing agreement with the FTC. The parties remain committed to the transaction and are working cooperatively with the FTC in connection with its review.

    Full Content: Financial Times

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.